The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre

European Journal of Cancer

Volumn 50, Issue 16, 2014, Pages 2763-2770

  McVeigh, Terri Patricia ^a   Hughes, Lauren M ^a   Miller, Nicola ^a   Sheehan, Margaret ^b   Keane, Maccon ^c   Sweeney, Karl J ^b   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b BreastCheck   (Ireland)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemotherapy; Genomic assay; Genomic profiling; Individualised therapy; Oncotype; Oncotype DX; Recurrence score

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; ESTROGEN RECEPTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER TEST; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; GENOMICS; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TUMOR VOLUME; VISCERAL METASTASIS; BREAST NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; PROSPECTIVE STUDY; RISK; TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 84925433377     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.08.002     Document Type: Article

References (30)

1. H.M. Heneghan, R.S. Prichard, and A. Devaney Evolution of breast cancer management in Ireland: a decade of change BMC Surg 9 1 2009
2. A.E. Giuliano, K.K. Hunt, and K.V. Ballman Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial JAMA 305 6 2011 569 575
3. T. Sørlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 2001 10869 10874
4. C.M. Perou, T. Sørile, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
5. B.D. Lehmann, J.A. Bauer, and X. Chen Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 7 2011 2750 2767
6. H.L. Howe Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998 Breast Cancer Res Treat 90 3 2005 223 232
7. M. Clarke, R. Collins, and C. Davies Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 9132 1998 930 942
8. C. Oakman, S. Bessi, and E. Zafarana Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer Breast Cancer Res 11 2 2009 205
9. S. Paik, G. Tang, and S. Shak Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 23 2006 3726 3734
10. L. Harris, H. Fritsche, and R. Mennel American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 33 2007 5287 5312
11. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011 Ann Oncol 22 8 2011 1736 1747
12. J.J. Carlson, and J.A. Roth The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis Breast Cancer Res Treat 141 1 2013 13 22
13. M. Cronin, M. Pho, and D. Dutta Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay Am J Pathol 164 1 2004 35 42
14. S. Paik, S. Shak, and G. Tang A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer New Engl J Med 351 27 2004 2817 2826
15. M.E.C. Sandberg Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study PLoS ONE 7 10 2012
16. J.A. Sparano TAILORx: Trial Assigning Individualized Options for Treatment (Rx) Clin Breast Cancer 7 4 2006 347 350
17. Kelly CM. Oncotype-DX® gene expression profile and chemotherapy decision-making in patients with early stage breast cancer. Irish Society of Medical Oncology guideline; 2011.
18. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 5 1991 403 410
19. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 6 2010 1471 1474
20. G. Tang, S. Shak, and S. Paik Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 Breast Cancer Res Treat 127 1 2011 133 142
21. T. Sørlie Molecular portraits of breast cancer: tumour subtypes as distinct disease entities Eur J Cancer 40 18 2004 2667 2675
22. B. Fisher, J.H. Jeong, and J. Bryant Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 9437 2004 858 868
23. R.W. Carlson, E. Brown, and H.J. Burstein NCCN Task Force report: adjuvant therapy for breast cancer JNCCN J Natl Comp Cancer Netw 4 suppl. 1 2006 S-1 S-26
24. M.H. Galea, R.W. Blamey, C.E. Elston, and I.O. Ellis The Nottingham prognostic index in primary breast cancer Breast Cancer Res Treat 22 3 1992 207 219
25. C. Markopoulos Overview of the use of Oncotype DX((R)) as an additional treatment decision tool in early breast cancer Expert Rev Anticancer Ther 13 2 2013 179 194
26. J. Hornberger Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review J Natl Cancer Inst 104 14 2012 1068 1079
27. C.A. Drukker, H.C. Van Den Hout, G.S. Sonke, and E. Brain Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature Eur J Cancer 50 6 2014 1045 1054
28. D. Zardavas, F. Ades, I.B. Spasojevic, and L. Pugliano Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO) Ann Oncol 25 8 2014 1558 1562
29. W. Eiermann, M. Rezai, and S. Kümmel The 21-gene recurrence score assay impacts adjuvant therapy recommendations for er-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use Ann Oncol 24 3 2013 618 624
30. N. Harbeck, K. Sotlar, R. Wuerstlein, and S. Doisneau-Sixou Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow Cancer Treat Rev 40 3 2014 434 444